Dyne Therapeutics, INC. (DYN) — SEC Filings

Q: What are the key financial highlights for Dyne Therapeutics, INC.?

Key financial highlights for Dyne Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Dyne Therapeutics, INC.?

Key executives at Dyne Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Dyne Therapeutics, INC. stock?

Risk factors for Dyne Therapeutics, INC. (DYN) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Dyne Therapeutics, INC.?

Forward-looking statements and predictions from Dyne Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Dyne Therapeutics, INC.. Recent 4 filing on Apr 22, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Dyne Therapeutics, INC. on SEC EDGAR

Overview

Dyne Therapeutics, INC. (DYN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 22, 2026: On April 22, 2026, Dyne Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The filing details transactions that occurred on April 20, 2026. The report was accepted by the SEC on April 22, 2026.

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 2 bullish, 43 neutral, 3 mixed. The dominant filing sentiment for Dyne Therapeutics, INC. is neutral.

Filing Type Overview

Dyne Therapeutics, INC. (DYN) has filed 1 4, 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G, 12 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (48)

Dyne Therapeutics Files Form 4 on Ownership Changes — 4 · Apr 22, 2026 Risk: low
On April 22, 2026, Dyne Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The filing details transactions that occurre
Dyne Therapeutics Announces Executive and Director Changes — 8-K · Dec 23, 2025 Risk: low
Dyne Therapeutics, Inc. announced on December 22, 2025, changes in its executive and director roles. The company filed a Form 8-K detailing the departure of cer
Dyne Therapeutics Files 8-K with Material Agreement — 8-K · Dec 10, 2025 Risk: medium
On December 9, 2025, Dyne Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
8-K Filing — 8-K · Dec 8, 2025
Dyne's Q3 Loss Widens on Soaring R&D, Bolsters Cash with Offerings — 10-Q · Nov 5, 2025 Risk: high
Dyne Therapeutics, Inc. reported a net loss of $108.041 million for the three months ended September 30, 2025, an increase from $97.125 million in the same peri
Dyne Therapeutics Reports Officer and Director Changes — 8-K · Oct 2, 2025 Risk: medium
Dyne Therapeutics, Inc. filed an 8-K on October 2, 2025, reporting changes effective October 1, 2025. The filing indicates a departure of directors or certain o
Dyne Therapeutics Files 8-K — 8-K · Aug 4, 2025 Risk: low
Dyne Therapeutics, Inc. filed an 8-K on August 4, 2025, to report on other events and a Regulation FD disclosure. The filing does not contain specific financial
Dyne's Net Loss Widens to $145.8M Amid R&D Ramp-Up — 10-Q · Jul 28, 2025 Risk: high
Dyne Therapeutics, Inc. reported no revenue for the six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for the si
Dyne Therapeutics Files 8-K with Material Agreement Details — 8-K · Jul 1, 2025 Risk: medium
On June 30, 2025, Dyne Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial sta
Dyne Therapeutics Enters Material Definitive Agreement — 8-K · Jun 30, 2025 Risk: medium
On June 27, 2025, Dyne Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation
Dyne Therapeutics Files 8-K for Regulatory Updates — 8-K · Jun 17, 2025 Risk: low
Dyne Therapeutics, Inc. filed an 8-K on June 17, 2025, to report on other events and provide financial statements and exhibits. The filing does not detail speci
Dyne Therapeutics Files 8-K on Security Holder Votes — 8-K · Jun 5, 2025 Risk: low
Dyne Therapeutics, Inc. filed an 8-K on May 30, 2025, to report on the submission of matters to a vote of its security holders. The filing does not detail the s
Dyne Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
Dyne Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business act
Dyne Therapeutics Executive Compensation Revealed — DEF 14A · Apr 15, 2025 Risk: low
Dyne Therapeutics, Inc. filed its DEF 14A on April 15, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes
Dyne Therapeutics Files 8-K on Officer/Director Changes — 8-K · Mar 20, 2025 Risk: medium
Dyne Therapeutics, Inc. filed an 8-K on March 20, 2025, reporting events as of March 17, 2025. The filing primarily concerns the departure of directors or certa
Dyne Therapeutics Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
Dyne Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, detailing its fiscal year ending December 31, 2024. The company, focused on pharmaceutical pre
Dyne Therapeutics Files Current Report — 8-K · Jan 10, 2025 Risk: low
Dyne Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting its status as a Delaware corporation with its principal executive offices in Waltham, Massac
SC 13G Filing — SC 13G · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 14, 2024
Dyne Therapeutics Files 8-K — 8-K · Nov 12, 2024 Risk: low
Dyne Therapeutics, Inc. filed an 8-K on November 12, 2024, to report other events and financial statements/exhibits. The filing does not contain specific detail
SC 13G Filing — SC 13G · Nov 12, 2024
Dyne Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Dyne Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results, including details on its cash and c
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
SC 13G/A Filing — SC 13G/A · Nov 8, 2024
SC 13G/A Filing — SC 13G/A · Nov 4, 2024
SC 13G/A Filing — SC 13G/A · Oct 22, 2024
8-K Filing — 8-K · Sep 3, 2024
Dyne Therapeutics Q2 2024 Update — 10-Q · Aug 12, 2024 Risk: medium
Dyne Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position, including marketable securities and
Dyne Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 24, 2024 Risk: low
Dyne Therapeutics, Inc. filed an 8-K on May 24, 2024, reporting on matters submitted to a vote of its security holders on May 22, 2024. The filing details the c
Dyne Therapeutics Files 8-K: Material Agreement & Other Events — 8-K · May 22, 2024 Risk: medium
On May 21, 2024, Dyne Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and
Dyne Therapeutics Partners with Pfizer for DMD Drug — 8-K · May 20, 2024 Risk: medium
Dyne Therapeutics, Inc. announced on May 20, 2024, that it has entered into a clinical collaboration with Pfizer Inc. to evaluate Dyne's novel antibody-oligonuc
Dyne Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: medium
Dyne Therapeutics, Inc. (DYN) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Dyne Therapeutics, Inc. reported financial results for the quarter en
Dyne Therapeutics Announces 2024 Annual Meeting of Stockholders on May 22 — DEF 14A · Apr 5, 2024 Risk: low
Dyne Therapeutics, Inc. (DYN) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Dyne Therapeutics, Inc. will hold its 2024 Annual Meeting of Stoc
SC 13G Filing — SC 13G · Apr 4, 2024
Dyne Therapeutics Appoints New CEO, Dr. Kristin Yarema — 8-K · Mar 25, 2024 Risk: medium
Dyne Therapeutics, Inc. announced on March 21, 2024, the appointment of Dr. Kristin Yarema as Chief Executive Officer and a member of the Board of Directors, ef
Dyne Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 5, 2024 Risk: medium
Dyne Therapeutics, Inc. (DYN) filed a Annual Report (10-K) with the SEC on March 5, 2024. Dyne Therapeutics, Inc. filed its 2023 Form 10-K on March 5, 2024, rep
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
MPM BioVentures Trims Dyne Therapeutics Stake to 9.9% — SC 13G/A · Feb 12, 2024 Risk: medium
MPM BioVentures 2018, L.P. and its affiliated entities, including MPM Asset Management Investors BV2018 LLC, filed an amended Schedule 13G/A on February 12, 202
Atlas Venture Amends Dyne Therapeutics Stake as of Dec 31, 2023 — SC 13G/A · Feb 9, 2024 Risk: low
Atlas Venture Fund XI, L.P. and its affiliated entities (collectively, "Atlas Venture") filed an amended SC 13G/A on February 9, 2024, indicating a change in th
BlackRock Discloses 9.9% Stake in Dyne Therapeutics — SC 13G · Jan 29, 2024
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds 5,745,466 shares of Dyne Therapeutics, Inc. common stock as of December 31,
Deep Track Capital Maintains 2M Share Stake in Dyne Therapeutics — SC 13G/A · Jan 19, 2024
Deep Track Capital, LP, a Delaware-based investment firm, filed an amended SC 13G/A on January 19, 2024, disclosing its beneficial ownership in Dyne Therapeutic
Dyne Therapeutics Files 8-K on Material Definitive Agreement — 8-K · Jan 5, 2024
Dyne Therapeutics, Inc. filed an 8-K on January 4, 2024, to report an "Entry into a Material Definitive Agreement" and "Other Events." While the filing indicate
Dyne Therapeutics Files 8-K, Confirms Emerging Growth Status — 8-K · Jan 4, 2024
Dyne Therapeutics, Inc. filed an 8-K on January 4, 2024, to report an "Other Event." This filing indicates that Dyne Therapeutics is an "emerging growth company
Dyne Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — 8-K · Jan 3, 2024
Dyne Therapeutics, Inc. filed an 8-K on January 3, 2024, to report a routine administrative update, specifically regarding its common stock, which trades under

Risk Profile

Risk Assessment: Of DYN's 28 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Dyne Therapeutics, INC.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: $0
Net Income: -$334.259M
EPS: -$2.74
Debt-to-Equity: 0.14
Cash Position: $573.610M
Operating Margin: N/A
Total Assets: $867.059M
Total Debt: $99.147M

Key Executives

Rhodes Jason P
Josh Brumm
John G. Cox
Doug Kerr
Carlo Incerti, M.D.
Catherine Stehman-Breen, M.D.
Dr. Kristin Yarema
Joshua Brumm
Ansbert Gadicke
Luke Evnin
Todd Foley

Industry Context

Dyne Therapeutics operates in the rapidly evolving and highly competitive gene therapy sector. This industry is characterized by significant scientific innovation, substantial R&D investment, and a complex regulatory landscape. Key trends include the development of novel delivery systems, targeting rare genetic diseases, and increasing collaboration between biotech firms and larger pharmaceutical companies.

Top Tags

biotech (6) · corporate-governance (5) · material-agreement (5) · financials (5) · regulatory-filing (4) · 10-Q (4) · institutional-ownership (4) · 8-K (3) · filing (3) · amendment (3)

Key Numbers

Filing Date: 2026-04-22 — Date the Form 4 was filed and accepted by the SEC.
Period of Report: 2026-04-20 — Date of the transactions reported in the Form 4.
Net Loss: $334.259M — Increased from $227.876M in 2024 for the nine-month period, indicating higher operational burn.
Research and Development Expenses: $302.902M — Increased 51.7% from $199.601M in 2024 for the nine-month period, reflecting intensified pipeline development.
Cash and Cash Equivalents: $573.610M — Increased from $435.449M at Dec 31, 2024, providing a stronger liquidity position.
Proceeds from Public Offering: $215.803M — Significant capital raised in Q3 2025, bolstering cash reserves.
Proceeds from At-the-Market Offering: $140.653M — Additional capital raised in Q1 2025, contributing to liquidity.
Long-term Debt, Net: $99.147M — New debt incurred in 2025, adding to financial obligations.
Common Shares Outstanding: 142,613,248 — Increased from 102,318,629 at Dec 31, 2024, due to equity offerings, indicating dilution.
R&D Expense Increase: 51.7% — Percentage increase in R&D for the nine months ended Sept 30, 2025, compared to 2024.
Net Loss Per Share (Q3 2025): $0.76 — Lower than $0.96 in Q3 2024 despite higher net loss, due to increased share count.
Earliest Commercialization Expectation: 2027 — The earliest year Dyne expects to commercialize any product candidate, if ever.
R&D Expenses: $124.3M — Increased from $102.1M in prior year period, indicating pipeline advancement.
Initial Loan Tranche: $20.0M — Drawn from Hercules Capital, boosting liquidity.
Marketable Securities: $350.0M — As of June 30, 2025, compared to $300.0M at Dec 31, 2024.

Forward-Looking Statements

{"claim":"Dyne Therapeutics' stock price may experience short-term volatility due to the perceived reduction in institutional confidence.","entity":"Dyne Therapeutics, Inc.","targetDate":"Q1 2024","confidence":"medium"}
{"claim":"Other institutional investors might re-evaluate their positions in Dyne Therapeutics following this filing.","entity":"Institutional Investors","targetDate":"Q2 2024","confidence":"low"}
{"claim":"Atlas Venture will continue to be a significant institutional holder in Dyne Therapeutics.","entity":"Atlas Venture Fund XI, L.P.","targetDate":"2025-02-09","confidence":"high"}

Related Companies

HRCC · DYNE · HTGC · PFE · EDIT

Frequently Asked Questions

What are the latest SEC filings for Dyne Therapeutics, INC. (DYN)?

Dyne Therapeutics, INC. has 48 recent SEC filings from Jan 2024 to Apr 2026, including 20 8-K, 12 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of DYN filings?

Across 48 filings, the sentiment breakdown is: 2 bullish, 43 neutral, 3 mixed. The dominant sentiment is neutral.

Where can I find Dyne Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Dyne Therapeutics, INC. (DYN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Dyne Therapeutics, INC.?

Key financial highlights from Dyne Therapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for DYN?

The investment thesis for DYN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Dyne Therapeutics, INC.?

Key executives identified across Dyne Therapeutics, INC.'s filings include Rhodes Jason P, Josh Brumm, John G. Cox, Doug Kerr, Carlo Incerti, M.D. and 6 others.

What are the main risk factors for Dyne Therapeutics, INC. stock?

Of DYN's 28 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 11 low-risk.

What are recent predictions and forward guidance from Dyne Therapeutics, INC.?

Recent forward-looking statements from Dyne Therapeutics, INC. include guidance on {"claim":"Dyne Therapeutics' stock price may experience short-term volatility due to the perceived reduction in institut and 2 other predictions.